Shots:Biocon Biologics has expanded its strategic collaboration with Civica to commercialize Insulin Glargine in the USBiocon Biologics & Civica entered into a multi-year exclusive distributorship where Biocon will manufacture & supply Insulin Glargine, & Civica will handle its commercialization in the US under its own label, incl. the CalRx brand in CaliforniaNo…
The peptide therapeutics market in North America and beyond is evolving fast, and 2025 is set to be a groundbreaking year.Whether you’re a researcher involved in peptide drug clinical trials, an investor in different pharmaceutical companies, or just curious about the future of medicine and drug discovery, understanding various peptide therapeutics market trends will…
Shots:Regeneron has entered into an in-licensing agreement with Hansoh for exclusive global clinical development & commercialization rights of HS-20094, excl. Mainland China, Hong Kong & MacauAs per the deal, Hansoh will receive $80M upfront & ~$1.93B in development, regulatory & sales milestones, with low double digits royalties on sales in Regeneron-licensed areasHS-20094…
Statistics show that at least 129 million people in the United States have a chronic illness. To effectively deal with chronic illnesses, one needs a thorough approach that includes customized supplements and medication. The management of these prolonged conditions requires consistent attention to prevent complexities while ensuring better living standards for patients.Continue reading to learn about…
These days, Ozempic is one of the most popular prescription medications for blood glucose control (or, in other words, blood sugar control). With its help, a great number of people living with diabetes mellitus manage to control their blood glucose levels (or, in other words, blood sugar levels) easily and effectively. But what differentiates Ozempic…
Shots: Novo Nordisk’s Awiqli (QW basal insulin icodec) has received CHMP’s positive opinion and recommending it for the final approval which is anticipated in next ~67days/ ~2mos The opinion was supported by the six P-IIIa (ONWARDS) study assessing the safety & efficacy of Awiqli in type 1 & type 2 diabetes adults (n= >4,000) incl.…
Shots:Paul talked about the approval of the Lyumjev Injection for the improvement of glycemic control in children and adolescents with diabetes. He also shared various details about LyumjevPaul further discussed the study design and the key findings from the registrational PRONTO-Peds studyThe interview also talks about Lilly’s Diabetes Solution Center which helps eligible…
Shots:Jason shared his views on the launch of Metabolon, Inc.’s new Oxysterols Targeted Panel, highlighting its key features He told how the panel measures 12 oxysterols and related sterols of biological significance to identify biomarkers for the prediction and early detection of cardiovascular diseases, neurodegenerative diseases, and cancer The interview gives a profound understanding…
The 15th and 16th of February saw the Global PHT Expo & Summit taking place at the Hyatt Centric in New Delhi, India.Through Global PHT Summit, it was for the first time that the pharma, healthcare, and technology veterans, pioneers, and professionals converged on the same platform to impart their knowledge on the best & futuristic PHT practices. The theme of the event…
Shots:Dr. Navdeep spoke about the data presented at the ASN Kidney Week 2022 emphasizing on the urgent need for early screening of chronic kidney diseaseHelen Yeh talked about the treatment of CKD with Farxiga. She also focused on the patient support programs by AstraZeneca for the early diagnosis and screening of patientsThe…

